This Article Full Text Full Text (PDF) All Versions of this Article: 43/4/785    most recent 01.HYP.0000125698.00128.64v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Azizi, M. Articles by Ménard, J. Search for Related Content PubMed PubMed Citation Articles by Azizi, M. Articles by Ménard, J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB FUROSEMIDE Related Collections Clinical Studies

(Hypertension. 2004;43:785.)
© 2004 American Heart Association, Inc.

Scientific Contributions

Integrating Drug Pharmacokinetics for Phenotyping Individual Renin Response to Angiotensin II Blockade in Humans

Michel Azizi; Alvine Bissery; Maxime Lamarre-Cliche; Joël Ménard

From the Clinical Investigation Center 9201, Assistance Publique des Hôpitaux de Paris/INSERM (M.A., A.B., J.M.), Hôpital Européen Georges Pompidou, Paris, France; and Institut de Recherches Cliniques de Montréal (M.L.-C.), Montréal, Québec, Canada.

Correspondence to Dr Michel Azizi, Centre d’Investigations Cliniques, AP-HP/INSERM, Hôpital Européen Georges Pompidou, 20-40 rue Leblanc, 75908 Paris cedex 15, France. E-mail michel.azizi{at}egp.ap-hop-paris.fr

Renin release into plasma has been used to investigate the drug dose-dependence of renin-angiotensin system inhibition because it is proportional to the interruption of the permanent negative feedback loop of angiotensin II on renin secretion. We investigated the 24-hour between-subject differences in renin profiles by analyzing the time-dependence of individual renin responses in 16 mildly sodium-depleted normotensive subjects exposed in a 4-period crossover study to single oral doses of 8- and 16-mg (C8 and C16) candesartan cilexetil and 80- and 160-mg (V80 and V160) valsartan. C8 had a similar effect to V160 in terms of the increase in active renin concentration and decrease in blood pressure. C16 had the strongest effect and V80 the weakest effect on renin release. Within- and between-subject variability was more marked for valsartan pharmacokinetics than for candesartan pharmacokinetics and influenced variability in renin response. To eliminate some of the variability caused by the pharmacokinetics of each drug, we corrected the area under time curve of plasma renin levels by that of plasma drug levels to obtain an individual normalized index of renin release or "renin/pharmacokinetic index". In these experimental conditions, this index was found to be a reproducible individual characteristic affecting renin response, in addition to the pharmacokinetics and pharmacological properties of angiotensin II type-1 receptor antagonists. The pharmacokinetic–pharmacodynamic model of renin release described here could be of value for the identification and investigation of renin release abnormalities in patients with hypertension and for the comparison of renin-angiotensin system blockers.

Key Words: blood pressure • renin • angiotensin antagonist

This article has been cited by other articles:

				A. Casselbrant, A. Edebo, P. Hallersund, E. Spak, H. F. Helander, C. Jonson, and L. Fandriks Angiotensin II receptors are expressed and functional in human esophageal mucosa Am J Physiol Gastrointest Liver Physiol, November 1, 2009; 297(5): G1019 - G1027. [Abstract] [Full Text] [PDF]

				M. Krop, I. M. Garrelds, R. J.A. de Bruin, J. M.G. van Gool, N. D.L. Fisher, N. K. Hollenberg, and A.H. Jan Danser Aliskiren Accumulates in Renin Secretory Granules and Binds Plasma Prorenin Hypertension, December 1, 2008; 52(6): 1076 - 1083. [Abstract] [Full Text] [PDF]

				W. W. Batenburg, R. J.A. de Bruin, J. M.G. van Gool, D. N. Muller, M. Bader, G. Nguyen, and A. H. J. Danser Aliskiren-Binding Increases the Half Life of Renin and Prorenin in Rat Aortic Vascular Smooth Muscle Cells Arterioscler Thromb Vasc Biol, June 1, 2008; 28(6): 1151 - 1157. [Abstract] [Full Text] [PDF]

				M. Azizi, J. Menard, A. Bissery, T.-T. Guyene, and A. Bura-Riviere Hormonal and Hemodynamic Effects of Aliskiren and Valsartan and Their Combination in Sodium-Replete Normotensive Individuals Clin. J. Am. Soc. Nephrol., September 1, 2007; 2(5): 947 - 955. [Abstract] [Full Text] [PDF]

				M. Azizi, J. Menard, A. Bissery, T.-T. Guyenne, A. Bura-Riviere, S. Vaidyanathan, and R. P. Camisasca Pharmacologic Demonstration of the Synergistic Effects of a Combination of the Renin Inhibitor Aliskiren and the AT1 Receptor Antagonist Valsartan on the Angiotensin II-Renin Feedback Interruption J. Am. Soc. Nephrol., December 1, 2004; 15(12): 3126 - 3133. [Abstract] [Full Text] [PDF]